Lenvatinib-Induced Tumor Lysis Syndrome in Advanced Hepatocellular Carcinoma

This case report describes a 48-year-old man with hepatocellular carcinoma who developed tumor lysis syndrome (TLS) after 7 days of starting lenvatinib therapy. The patient was hospitalized and received appropriate interventions, including aggressive hydration, allopurinol, rasburicase, and electrol...

Descripción completa

Detalles Bibliográficos
Autores principales: Goyal, Manjeet Kumar, Singh, Arshdeep, Kumar Gupta, Yogesh, Kaur Dhaliwal, Kanwarpal, Sood, Ajit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479354/
https://www.ncbi.nlm.nih.gov/pubmed/37674881
http://dx.doi.org/10.14309/crj.0000000000001139
Descripción
Sumario:This case report describes a 48-year-old man with hepatocellular carcinoma who developed tumor lysis syndrome (TLS) after 7 days of starting lenvatinib therapy. The patient was hospitalized and received appropriate interventions, including aggressive hydration, allopurinol, rasburicase, and electrolyte management. The patient's condition improved, and he was eventually discharged from the hospital. This case highlights the potential risk of TLS in patients with hepatocellular carcinoma receiving lenvatinib therapy, even after a short duration, and emphasizes the importance of early recognition and management of TLS to prevent serious complications.

Ejemplares similares